Onkologie und Versorgung in Fach- und Publikumsmedien

Dietlein M et al (2016) Procedure guidelines for radioiodine therapy of differentiated thyroid cancer. Version 4. Nuklearmedizin 55:77–89 Kolbert KS et al (2007) Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3‑dimensional internal dosimetry software. J Nucl Med 48:143–149 Brown AP et al (2008) The risk of second primary malignancies up to three decades after the treatment of differentiated cancer. J Clin Endocrinol Metab 93:504–515 Haugen BRM et al (2015) 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):1–133 Clement SC et al (2015) Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma – A systematic review. Cancer Treat Rev 41:925–934 Teng CJ et al (2016) Use of radioactive iodine for thyroid cancer and risk of second primary malignancy: a nationwide population-based study. J Natl Cancer Inst 108(2):djv314 Liou MJ et al (2016) Therapeutic outcome of second primary malignancies in patients with well-differentiated thyroid cancer. Int J Endocrinol 2016:9570171 Cho YY et al (2015) Elevated risks of subsequent primary malignancies in patients with thyroid cancer: a nationwide, population-based study in Korea. Cancer 121:259–268 Mathur A et al (2015) Is there an increased risk of second primary malignancy after diagnosis of thyroid cancer? Cancer 121:166–168 Dennert G, Horneber M (2006) Selenium for alleviating the side effects of chemotherapy, radiotherapy and surgery in cancer patients. Cochrane Database Syst Rev. doi:10.1002/14651858.CD005037.pub2 Deutsche Gesellschaft für Ernährung (2015) Ausgewählte Fragen und Antworten zu Selen. https://www.dge.de/fileadmin/public/doc/ws/faq/FAQs-Selen.pdf. Zugegriffen: 6. Okt. 2016 Rodemann HP et al (1999) Relevance of the radioprotective effect of sodium selenite. Med Klin (Munich) 94(Suppl 3):39–41 Büntzel J et al (2010) Limited effects of selenium substitution in the prevention of radiation-associated toxicities. Results of a randomized study in head and neck cancer patients. Anticancer Res 30(5):1829–1832 Mücke R et al (2010) Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology. Int J Radiat Oncol Biol Phys 78(3):828–835 Arends J et al (2015) Klinische Ernährung in der Onkologie. S3-Leitlinie. Aktuel Ernahrungsmed 40:e1–e74 Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e. V., Onkopedia (2015) Selen – Einsatz während der Tumortherapie. https://www.onkopedia.com/de/onkopedia/guidelines/selen-einsatz-waehrend-der-tumortherapie. Zugegriffen: 7. Okt. 2016 Arbeitsgemeinschaft Gynäkologische Onkologie, Kommission Mamma (2016) Diagnostik und Therapie von Patientinnen mit primärem und metastasiertem Brustkrebs. http://www.ago-online.de/fileadmin/downloads/leitlinien/mamma/Maerz2016/de/Alle_aktuellen_Empfehlungen_2016.pdf. Zugegriffen: 6. Okt. 2016 Robert-Koch-Institut (Hrsg) (2016) GBE Themenheft Hepatitis C. Gesundheitsberichterstattung des Bundes. Gemeinsam getragen von RKI und Destatis. Robert Koch Institut, Berlin Robert Koch-Institut (2016) Zur Situation bei wichtigen Infektionskrankheiten in Deutschland. Hepatits C im Jahr 2015. Epidemiologisches Bulletin Nr. 29. http://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2016/Ausgaben/29_16.pdf?__blob=publicationFile. Zugegriffen: 12. Okt. 2016 Wirth TC, Manns MP (2016) The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma. Ann Oncol 27(8):1467–1474 S3-Leitlinie (2015) Aktuelle Empfehlung zur Therapie der chronischen Hepatitis C. http://www.dgvs.de/fileadmin/user_upload/Leitlinien/Therapie_der_chronischen_Hepatitis_C/09.07.2015_Aktuelle_Empfehlung_zur_Therapie_der_chronischen_Hepatitis_C.pdf. Zugegriffen: 7. Okt. 2016 Morgan RL et al (2013) Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 158(1):329–337 Alves-Filho JC, Palsson-McDermott EM (2016) Pyruvate kinase M2: a potential target for regulating inflammation. Front Immunol 7:145 Yang W, Lu Z (2015) Pyruvate kinase M2 at a glance. J Cell Sci 128(9):1655–1660 Iqbal MA et al (2014) Pyruvate kinase M2 and cancer: an updated assessment. FEBS Lett 588(16):2685–2692 Muñoz-Colmenero A et al (2015) Plasma tumor M2-Pyruvate kinase levels in different cancer types. Anticancer Res 35(7):4271–4276 Palsson-McDermott EM, O’Neill LA (2013) The Warburg effect then and now: from cancer to inflammatory diseases. Bioessays 35(11):965–973 Staib P et al (2006) Plasma levels of tumor M2-pyruvate kinase should not be used as a tumor marker for hematological malignancies and solid tumors. Clin Chem Lab Med 44(1):28–31 Hathurusinghe HR et al (2007) Current status of tumor M2 pyruvate kinase (tumor M2-PK) as a biomarker of gastrointestinal malignancy. Ann Surg Oncol 14(10):2714–2720 Hennigs A et al (2016) Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study. BMC Cancer 16:734 Lehmann B et al (2016) Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLOS ONE 11(6):e0157368 Coates AS et al (2015) Tailoring therapies – improving the management of early breast cancer: St Gallen International Expert Consensus on the primary therapy of early breast cancer 2015. Ann Oncol 26(8):1533–1546 Kommission Mamma der AGO (2016) Diagnostik und Therapie von Patientinnen mit primärem und metastasiertem Brustkrebs. http://www.ago-online.de/fileadmin/downloads/leitlinien/mamma/Maerz2016/de/Alle_aktuellen_Empfehlungen_2016.pdf. Zugegriffen: 10. Okt. 2016 Von Minckwitz G et al (2015) Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (Geparsixto). In: San Antonio Breast Cancer Symposium 2015. (Abstract S2-04) Sikov W et al (2015) Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: Calgb 40603 (Alliance). J Clin Oncol 33:13–21